You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海王英特龍(08329.HK)擬7650萬元收購北京中新藥業股份51%股權
格隆匯 04-22 19:30

格隆匯 4 月 22日丨海王英特龍(08329.HK)發佈公吿,2021年4月22日,買方(深圳海王長健醫藥有限公司,公司的全資附屬公司)與賣方(史新龍、史楠楠及史倩)訂立股權轉讓協議,據此,賣方有條件同意出售目標公司(即北京中新藥業股份有限公司)的51%股權,代價為人民幣7650萬元。收購事項完成後,目標公司將成為公司的非全資附屬公司。

目標公司為一間於中國註冊成立的有限責任公司,主要從事口服固體制劑的生產。目標公司在研發及製造藥品方面擁有數十年經驗,現時為中國一家藥品製造商。董事會認為,透過收購目標公司,集團將可加強、擴展及多元化發展其於中國研發和製造藥品的業務。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account